Home Cart Sign in  
Chemical Structure| 1622902-68-4 Chemical Structure| 1622902-68-4

Structure of Abrocitinib
CAS No.: 1622902-68-4

Chemical Structure| 1622902-68-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Abrocitinib is a potent and selective JAK1 inhibitor with IC50s of 29 and 803nM for JAK1 and JAK2, respectively.

Synonyms: Pf 04965842

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Abrocitinib

CAS No. :1622902-68-4
Formula : C14H21N5O2S
M.W : 323.41
SMILES Code : CCCS(=O)(N[C@H]1C[C@@H](N(C)C2=C3C(NC=C3)=NC=N2)C1)=O
Synonyms :
Pf 04965842
MDL No. :MFCD30187577
InChI Key :IUEWXNHSKRWHDY-UHFFFAOYSA-N
Pubchem ID :78323835

Safety of Abrocitinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P264-P270-P301+P312+P330-P501

Related Pathways of Abrocitinib

epigenetics
RTK
JAK-STAT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
BV2 microglial cells 100 nM, 500 nM, or 1 μM 6 hours To evaluate the effects of Abrocitinib on microglial polarization. Results showed that Abrocitinib reduced the pro-inflammatory M1 microglia phenotype and shifted microglial polarization toward the anti-inflammatory M2 phenotype. PMC9688110

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice TEN model Oral 20 mg/kg Once daily Significantly reduced disease severity PMC11602713
C57BL/6 mice Fluid percussion injury (FPI) model Intragastric 10 mg/kg Once daily for 7 days To evaluate the effects of Abrocitinib on neuroinflammation and neuroprotection after traumatic brain injury (TBI). Results showed that Abrocitinib treatment shrunk the trauma lesions, improved neurological function, reduced blood-brain barrier leakage, improved intracranial blood flow, relieved inflammatory cell infiltration, and decreased levels of inflammatory cytokines. PMC9688110
BALB/c mice DNCB-induced AD mouse model Oral 10 or 15 mg/kg Daily administration, starting from the 4th week for 12 weeks To compare the therapeutic efficacy of PLAG and abrocitinib for severe AD treatment. Abrocitinib significantly improved AD skin lesions, but PLAG showed superior performance in reducing eosinophil infiltration. PMC11461884
Mice Aged mouse model of mechanical alloknesis Oral 15 mg/kg Single administration, mechanical alloknesis assay performed 30 min after administration To evaluate the inhibitory effect of abrocitinib on mechanical alloknesis in aged mice, results showed that abrocitinib significantly suppressed mechanical alloknesis. PMC11110811

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05689151 Atopic Dermatitis|Eczema RECRUITING 2027-05-31 CHU Amiens-Picardie - Site Nor... More >>d, Amiens, Somme, 80080, France|CHU Besancon - Hopital Jean Minjoz, Besancon, 25000, France|Ch William Morey, Chalon Sur Saone, 71100, France|Chu Estaing, Clermont Ferrand Cedex 1, 63003, France|CHU Clermont Ferrand - Hopital Gabriel Montpied, Clermont-Ferrand, 63000, France|Chu Dijon, Dijon, 21000, France|Hopital Claude Huriez, Lille, 59000, France|Hopital Saint Louis (APHP) - Service Hematologic Senior, Paris CEDEX 10, 75475, France|Hopital Bichat, Paris, 75018, France|CHU Lyon Sud, Pierre-Bénite, 69495, France|Hopital Bégin, Saint-Mande, 94160, France Less <<
NCT05602207 Atopic Dermatitis PHASE4 ACTIVE_NOT_RECRUITING 2025-08-25 Inno-6050 Site 22, Birmingham,... More >> Alabama, 35244, United States|Inno-6050 Site 13, Fountain Valley, California, 92708, United States|Inno-6050 Site 21, Miami Lakes, Florida, 33014, United States|Inno-6050 Site 19, Saint Petersburg, Florida, 33709, United States|Inno-6050 Site 16, Quincy, Massachusetts, 02169, United States|Inno-6050 Site 17, Auburn Hills, Michigan, 48326, United States|Inno-6050 Site 15, Winnipeg, Manitoba, R3C 0N2, Canada|Inno-6050 Site 18, Newmarket, Ontario, L3Y 5G8, Canada|Inno-6050 Site 11, Toronto, Ontario, M4W 2N4, Canada|Inno-6050 Site 10, Montreal, Quebec, H2X 2V1, Canada|Inno-6050 Site 14, Québec, Quebec, G1V 4X7, Canada|Inno-6050 Site 20, Québec, Quebec, G1W 4R4, Canada Less <<
NCT06807281 Atopic Dermatitis PHASE3 NOT_YET_RECRUITING 2032-01-17 -
NCT05038982 Prurigo Nodularis|Pruritus|Chr... More >>onic Pruritus|Chronic Prurigo|Skin Diseases Less << PHASE2 COMPLETED 2022-07-11 Johns Hopkins Outpatient Cente... More >>r, Baltimore, Maryland, 21205, United States Less <<
NCT05721937 Atopic Dermatitis RECRUITING 2027-12-31 Pfizer, New York, New York, 10... More >>001-2192, United States Less <<
NCT05391061 Dermatitis, Atopic RECRUITING 2027-11-22 Pfizer Tower, Seoul, 04631, Ko... More >>rea, Republic of Less <<
NCT05069831 Food Allergy PHASE1 RECRUITING 2025-06-25 Icahn School of Medicine at Mo... More >>unt Sinai, New York, New York, 10029, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.09mL

0.62mL

0.31mL

15.46mL

3.09mL

1.55mL

30.92mL

6.18mL

3.09mL

 

Historical Records

Categories